LncRNA ABHD11-AS1 Participates in the Progression of Cervical Carcinoma by Targeting miR-1254 and Is the Key to the Diagnosis and Treatment of Cervical Carcinoma in the Future

Figure 2

Clinical significance of LncRNA ABHD11-AS1 and miR-1254 in cervical carcinoma. . . (a) Comparison of expression levels of LncRNA ABHD11-AS1 in serum of cervical carcinoma patients before and after treatment. (b) Comparison of miR-1254 expression level in serum of cervical carcinoma patients before and after treatment. (c) Comparison of expression levels of LncRNA ABHD11-AS1 between patients with prognosis death and patients with survival. (d) Comparison of miR-1254 expression level between patients with prognosis death and patients with survival. (e) Predictive value of LncRNA ABHD11-AS1 for prognosis and death of cervical carcinoma patients. AUC: 0.904; 95% CI: 0.801–1.0; cutoff: 6.275; sensitivity: 88.89%; specificity: 90.00%; . (f) Predictive value of miR-1254 for prognosis and death of cervical carcinoma patients. AUC: 0.907; 95% CI: 0.800–1.015; cutoff: 3.095; sensitivity: 88.89%; specificity: 83.33%; . (g) Three-year survival curve of patients in group A and group B. (h) Three-year survival curve of patients in group C and group D.

(a)

(b)

(c)

(d)

(e)

(f)